ORIGINAL RESEARCH article
Front. Oncol.
Sec. Head and Neck Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1647606
This article is part of the Research TopicAdvancements in Personalized Medicine for Head and Neck Cancer: Molecular-based Approaches to Treatment and CareView all 10 articles
De-escalating adjuvant Therapy after pathologic complete response in oral squamous cell carcinoma: chemoradiotherapy benefits only high-risk subgroups
Provisionally accepted
- Henan Provincial Cancer Hospital, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The optimal adjuvant therapy for oral squamous cell carcinoma (SCC) patients achieving pathological complete response (pCR) after neoadjuvant immunochemotherapy (NAIC) remains uncertain. While radiotherapy (RT) and chemoradiotherapy (CRT) improve locoregional control, their comparative efficacy and toxicity profiles in this setting are poorly defined. Methods: Oral SCC patients with pCR post-NAIC were retrospectively enrolled and stratified into RT and CRT groups. Propensity score matching balanced baseline characteristics. Outcomes included 3-year locoregional control (LRC), overall survival (OS), and toxicity. Subgroup analyses evaluated treatment effects by radiologic extranodal extension (rENE) and tumor differentiation. Results: Among 116 patients analyzed (84 matched), CRT showed no significant LRC or OS benefit over RT alone in the overall cohort (LRC: HR 1.89, 95% CI 0.26–4.72, p=0.625; OS: HR 1.45, 95% CI 0.62–3.41, p=0.392). However, subgroup analyses revealed CRT improved outcomes in high-risk patients (rENE+ or poorly differentiated tumors), reducing recurrence by 50% (rENE+: HR 3.12, 95% CI 1.13–8.60, p=0.028; poor differentiation: HR 3.45, 95% CI 1.23–9.68, p=0.019) and enhancing 3-year OS (rENE+: 62.4% vs. 50.1%, p=0.036; poorly differentiated: 68.3% vs 53.8%, HR 2.88, p=0.022). CRT was associated with significantly higher acute and chronic toxicities (Grade 3–5 mucositis: 36.0% vs. 12.1%). Conclusion: CRT should be reserved for high-risk pCR patients (rENE+ or poorly differentiated tumors), while RT alone suffices for low-risk cases. This risk-adapted approach optimizes outcomes while minimizing toxicity.
Keywords: Chemoradiotherapy, locoregional control, oral squamous cell carcinoma, Pathological complete response, Radiotherapy
Received: 16 Jun 2025; Accepted: 27 Aug 2025.
Copyright: © 2025 Du, Liu, Yang and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei Du, Henan Provincial Cancer Hospital, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.